Elite Pharmaceuticals (OTCMKTS:ELTP) Sees Large Volume Increase – Here’s Why
by Sarita Garza · The Markets DailyShares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 351,820 shares traded hands during mid-day trading, an increase of 146% from the previous session’s volume of 142,816 shares.The stock last traded at $0.4820 and had previously closed at $0.50.
Elite Pharmaceuticals Trading Down 0.0%
The company has a quick ratio of 6.34, a current ratio of 8.04 and a debt-to-equity ratio of 0.06. The company has a market cap of $537.14 million, a price-to-earnings ratio of 50.04 and a beta of 0.32. The firm has a 50 day moving average price of $0.55 and a two-hundred day moving average price of $0.59.
Elite Pharmaceuticals Company Profile
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.